Anti-GD2 CAR T-cell therapy (Bambino Gesu Hospital and Research Institute/Bellicum)

抗GD2嵌合抗原T细胞疗法

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-GD2 CAR T-cell therapy (Bambino Gesu Hospital and Research Institute/Bellicum)
Drug Alias NameGD2-CART01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSolid tumoursDiffuse midline gliomaBrain Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBambino Gesu Hospital And Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesBambino Gesu Hospital And Research InstituteBellicum Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursDiffuse midline gliomaBrain Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A